Home > Insider Trading > Filing (0000919574-24-003356)

Filing Details

Accession Number:: 0000919574-24-003356
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-05-28 20:45:58
Reporting Period:: 2024-05-23

Accepted Time:: 2024-05-28 20:45:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1162194	Standard Biotools Inc.	LAB	Laboratory Analytical Instruments (3826)	770513190

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1534260	Casdin Partners Gp, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1534261	Casdin Capital, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1534264	Eli Casdin	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1534265	Casdin Partners Master Fund, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1823061	Casdin Private Growth Equity Fund, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	No	No
1864554	Casdin Private Growth Equity Fund Gp, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	No	No
1891102	Casdin Private Growth Equity Fund Ii, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	No	No
1919480	Casdin Private Growth Equity Fund Ii Gp, Llc	1350 Avenue Of The Americas, Suite 2600 New York NY 10019	Yes	No	No	No
1938709	Casdin Partners Fo1-Msv, Lp	C/O Casdin Partners Gp, Llc 1350 Avenue Of The Americas, Suite 2600 New York NY 10019	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-05-23	100,000	$2.60	46,075,821	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	13,939,637	Indirect	See footnote
Common Stock	103,556	Direct
Common Stock	2,744,219	Indirect	See footnote
Common Stock	1,200,000	Indirect	See footnote
Common Stock	7,548,000	Indirect	See footnote

Footnotes

The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
The securities are owned directly by Eli Casdin.
The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
The securities are owned directly by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II.